human gut flora

Overview

The human gut flora, also referred to as the gut microbiota or intestinal microbiome, comprises the vast and diverse community of microorganisms — predominantly bacteria, but also archaea, fungi, viruses, and protists — that colonize the gastrointestinal tract. Estimated to harbor trillions of microbial cells encoding tens of millions of genes, this ecosystem represents one of the most complex and metabolically active environments in the human body. The dominant bacterial phyla in healthy adults include Firmicutes, Bacteroidota (formerly Bacteroidetes), Actinobacteria, and Proteobacteria, with their relative abundances shaped by host genetics, age, diet, geographic origin, and pharmaceutical exposures.

Far from being passive residents, gut microorganisms perform critical physiological functions: fermenting dietary fiber into short-chain fatty acids (SCFAs), synthesizing vitamins, educating and calibrating the host immune system, maintaining intestinal barrier integrity, modulating bile acid metabolism, and producing a broad repertoire of bioactive Metabolites that circulate systemically. Disruption of this community — termed dysbiosis — has been linked to an expanding spectrum of conditions extending well beyond the gastrointestinal tract, including metabolic disorders, neurodegenerative diseases, cancers, autoimmune conditions, and psychiatric illnesses. The gut microbiota's capacity to influence remote organ systems via the gut-liver axis, gut-lung axis, and microbiota-gut-brain axis has positioned it as a central subject in translational medicine and multi-omics research.

Focus of Latest Publications

Recent research demonstrates that human gut flora plays a central role in regulating metabolic health, intestinal barrier integrity, and systemic aging phenotypes. Multiple studies employed multi-omics approaches—including metagenomic profiling, metabolomics, and transcriptomics—to characterize how gut microbiota composition and function mediate age-associated decline. Dietary polyphenol interventions, such as purple sweet potato anthocyanins, were shown to remodel aging-associated microbiota and restore intestinal epithelial barrier function through a "microbiota-autophagy-stem cell" axis, concurrently alleviating motor coordination impairment, hepatic lipid dysregulation, and insulin resistance. Similarly, wholegrain rye diets were investigated for their capacity to modulate gut microbiota composition in the context of weight loss and cardiometabolic risk reduction, contrasting with refined wheat consumption. Fecal microbiota transplantation experiments confirmed the causal contribution of microbiota remodeling to intestinal stem cell rejuvenation and systemic health outcomes.

The microbiota-gut-brain axis emerged as a unifying mechanism across multiple disease contexts. Fecal microbiota from elderly donors with comorbid Alzheimer's disease and type 2 diabetes showed the greatest dysbiosis, characterized by enrichment of pro-inflammatory taxa, depletion of butyrate-producing genera, and loss of neuroprotective metabolic pathways; transfer of this dysbiotic microbiota to recipient mice suppressed hippocampal neurotrophic gene expression and induced cognitive alterations. Pharmacological interventions targeting the microbiota—including sibelium prophylaxis for migraine and hydroxytyrosol from olive oil for posttraumatic stress responses—preserved or restored microbial diversity and stability, with effects attributed to preserved short-chain fatty acid (SCFA) production and reduced neuroinflammation. Conversely, pathological dietary patterns, such as habitual ultra-processed food intake in inflammatory bowel disease patients and type 2 diabetes-induced dysbiosis, were associated with intestinal barrier disruption, pro-inflammatory metabolite profiles, and exacerbation of systemic outcomes including periodontitis and impaired cardiometabolic health.

Emerging evidence implicates human gut flora dysbiosis in immune tolerance and cancer-related complications. Gut microbiota composition was identified as a potential mediator of immune-related adverse events in patients receiving immune checkpoint inhibitor immunotherapy, particularly ICI colitis. Multi-omics Mendelian randomization analysis causally linked specific gut microbial taxa and metabolic pathways—including valine, leucine, and isoleucine biosynthesis—to aortic stenosis risk through systemic inflammation and plasma metabolite alterations. Additionally, altered microbiota and reduced SCFA levels were documented in patients with acute ischemic stroke complicated by active cancer, suggesting that dysbiosis may contribute to stroke pathophysiology through metabolic and immune dysfunction. Collectively, these studies underscore human gut flora as a modifiable therapeutic target whose composition and metabolic output influence intestinal barrier function, systemic inflammation, neurological health, and age-associated disease susceptibility.